Complete response to erlotinib and bevacizumab in a patient with Biphenotypic (hepatobiliary) primary liver carcinoma

Keyphrases

• Aberrations 50%
• Bevacizumab 100%
• Biliary Tract Cancer 50%
• Biphenotypic 100%
• Complete Response 100%
• Epidermal Growth Factor Receptor Gene 50%
• Epidermal Growth Factor Receptor Inhibitors (EGFRI) 100%
• Erlotinib 100%
• Gene Locus 50%
• Genomic Analysis 50%
• Hepatobiliary 100%
• Hepatocellular Carcinoma 100%
• Intrahepatic Cholangiocarcinoma (iCCA) 100%
• Molecular Pathways 50%
• Overall Survival Prognosis 50%
• Primary Hepatocellular Carcinoma 100%
• R521K 50%
• Rare Tumors 100%
• Single nucleotide Variant 50%
• Targeted Therapy 100%
• Tumor 50%
• Tyrosine Kinase Inhibitor 50%
• Vascular Endothelial Growth Factor 50%
• Vascular Endothelial Growth Factor Inhibitors 50%
• Well-defined 50%

Medicine and Dentistry

• Bevacizumab 100%
• Biliary Tract Cancer 25%
• Cholangiocarcinoma 50%
• Epidermal Growth Factor Receptor 50%
• Epidermal Growth Factor Receptor Kinase Inhibitor 25%
• Erlotinib 100%
• Gene Locus 25%
• Genetics 25%
• Hepatocellular Carcinoma 100%
• Rare Tumor 50%
• Receptor Gene 25%
• Single Nucleotide Polymorphism 25%
• Targeted Therapy 50%
• Tumor 25%
• Tyrosine-Kinase Inhibitor 25%
• Vasculotropin 25%
• Vasculotropin Inhibitor 25%